This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wang, Y. Search for Related Content PubMed PubMed Citation Articles by Wang, Y. Related Collections Other myocardial biology Remodeling Hypertrophy Physiological and pathological control of gene expression

(Circulation Research. 2003;93:186.)
© 2003 American Heart Association, Inc.

Editorials

Fill a Gab(1) in Cardiac Hypertrophy Signaling

Search a Missing Link Between gp130 and ERK5 in Hypertrophic Remodeling in Heart

Yibin Wang

From the Division of Molecular Medicine, Department of Anesthesiology and Medicine, University of California, David Geffen School of Medicine, Los Angles, Calif.

Correspondence to Yibin Wang, Division of Molecular Medicine, Department of Anesthesiology and Medicine, University of California, David Geffen School of Medicine, Los Angles, CA 90095. E-mail ywangibi@ucla.edu

Key Words: cardiac hypertrophy • Gab-1 • scaffold protein • cytokine signaling • extracellular signal-regulated kinase 5

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Cardiac hypertrophy represents one of the most central issues in heart failure, involving many aspects of changes in cardiac myocyte from cellular morphology to gene expression and contractile function.^1,2 Although the process is at the beginning compensatory in response to hemodynamic load or myocardial injury, cardiac hypertrophy is often followed by pathological remodeling in myocardium and a transition to overt heart failure.³ A large number of extracellular ligands, their cognate receptors and corresponding intracellular signal transduction pathways have been implicated in the hypertrophic process from both in vitro and in vivo studies.^4–13 Among them, cardiotrophin-1 (CT-1) was discovered as a potent activator of cardiac hypertrophy¹⁴ that shares extensive sequence and functional similarities with leukemia inhibitory factor (LIF) as members of interleukin-6 (IL-6)–related cytokine family.¹⁵ LIF/CT-1 bind to gp130/LIF cytokine receptor ß heterodimer and activate downstream signaling pathways, including members of signal transducer and activator of transcription (STATs), mitogen-activated protein (MAP) kinases such as extracellular signal–regulated kinases (ERK1/2), and phosphatidylinositol 3-kinase (PI3K)/Akt.^15,16 Studies have demonstrated that both LIF and CT-1 promote myocyte hypertrophy, survival, and a unique pattern of embryonic/fetal gene induction.^17–22 LIF and CT-1 expression and gp130 signaling also correlated with mechanical stress in myocytes in culture²³ and human and experimental models of heart failure.^24–30 More significantly, targeted inactivation of gp130 in ventricular myocytes via Cre-loxP–mediated tissue-specific knockout resulted in rapid chamber dilation and a significant increase in myocyte apoptosis upon pressure overload.³¹ All these findings underscore the potential function of gp130 signaling in myocyte remodeling and survival in response . . . [Full Text of this Article]